U.S. Applied Therapeutics, Brown-Forman, Ulta Beauty
Nov 29 (Reuters) -Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Therapeutics, Brown-Forman and Ulta Beauty on Friday.
HIGHLIGHTS
* Applied Therapeutics Inc APLT.O: RBC cuts to sector perform from outperform |
* Brown-Forman BFb.N: Barclays cuts target price to $49 from $53 |
* Descartes Systems Group Inc DSGX.O: RBC raises target price to $133 from $115 |
* The J.M. Smucker Company SJM.N: Barclays raises target price to $126 from $121 |
* Ulta Beauty Inc ULTA.O: Citigroup raises target price to $390 from $345 |
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in alphabetical order.
* Applied Therapeutics Inc APLT.O: Baird cuts target price to $5 from $14 |
* Applied Therapeutics Inc APLT.O: RBC cuts target price to $4 from $12 |
* Applied Therapeutics Inc APLT.O: RBC cuts to sector perform from outperform |
* Autodesk Inc ADSK.O: Citigroup raises target price to $361 from $358 |
* Brown-Forman BFb.N: Barclays cuts target price to $49 from $53 |
* CF Industries Holdings Inc CF.N: Berenberg raises target price to $74 from $69 |
* Crowdstrike CRWD.O: Citigroup raises target price to $400 from $300 |
* Descartes Systems Group Inc DSGX.O: RBC raises target price to $133 from $115 |
* Domo Inc DOMO.O: TD Cowen raises target price to $10 from $9 |
* Equinix Inc EQIX.O: Truist Securities raises target price to $1,090 from $935 |
* Global Net Lease Inc GNL.N: Truist Securities cuts target price to $8 from $8.5 |
* J M Smucker Co SJM.N: Citigroup raises target price to $137 from $134 |
* Passage Bio Inc PASG.O: Wedbush assumes coverage with outperform rating |
* Passage Bio Inc PASG.O: Wedbush assumes coverage with price target $4 vs $3 |
* Pebblebrook Hotel Trust PEB.N: Stifel raises target price to $16.25 from $15 |
* Pfizer PFE.N: Berenberg raises target price to $29 from $27 |
* Piedmont Lithium Inc PLL.O: BMO raises target price to $14 from $9.5 |
* Plymouth Industrial REIT Inc PLYM.N: Truist Securities cuts PT to $22 from $27 |
* RadNet Inc RDNT.O: Truist Securities raises target price to $94 from $80 |
* Smurfit Westrock Plc SW.N: JP Morgan raises target price to $69 from $65 |
* Splash Beverage Group Inc SBEV.A: H.C. Wainwright cuts target price to $0.5 from $1 |
* The J.M. Smucker Company SJM.N: Barclays raises target price to $126 from $121 |
* TXNM Energy TXNM.N: Barclays raises target price to $52 from $46 |
* Ulta Beauty Inc ULTA.O: Citigroup raises target price to $390 from $345 |
* Urban Outfitters Inc URBN.O: Citigroup raises target price to $59 from $42 |
* Urban Outfitters Inc URBN.O: Citigroup raises to buy from neutral |
* Voyager Therapeutics Inc VYGR.O: Wedbush assumes coverage with outperform vs neutral rating |
* Voyager Therapeutics Inc VYGR.O: Wedbush assumes coverage with PT $11 vs $7 |
* Warner Music Group Corp WMG.O: Citigroup raises target price to $34 from $31 |
(Compiled by Bengaluru Newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
